The Role of Mitochondrial Dynamin in Stroke

Chenchen Li, Chunli Chen, Haiyun Qin, Chuncao Ao, Jinlun Chen, Jieqiong Tan, and Liuwang Zeng

1Department of Neurology, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China
2Center for Medical Genetics, School of Life Sciences, Central South University, Changsha, Hunan 410078, China
3Hunan Key Laboratory of Medical Genetics, Central South University, Changsha, Hunan 410078, China
4Hunan Key Laboratory of Animal Model for Human Diseases, Central South University, Changsha, Hunan 410078, China

Correspondence should be addressed to Liuwang Zeng; zengliuwang@csu.edu.cn

Received 12 December 2021; Accepted 17 April 2022; Published 6 May 2022

Academic Editor: Giulia Sita

Copyright © 2022 Chenchen Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Stroke is one of the leading causes of death and disability in the world. However, the pathophysiological process of stroke is still not fully clarified. Mitochondria play an important role in promoting nerve survival and are an important drug target for the treatment of stroke. Mitochondrial dysfunction is one of the hallmarks of stroke. Mitochondria are in a state of continuous fission and fusion, which are termed as mitochondrial dynamics. Mitochondrial dynamics are very important for maintaining various functions of mitochondria. In this review, we will introduce the structure and functions of mitochondrial fission and fusion related proteins and discuss their role in the pathophysiologic process of stroke. A better understanding of mitochondrial dynamin in stroke will pave way for the development of new therapeutic options.

1. Introduction

Stroke is divided into ischemic stroke and hemorrhagic stroke [1]. 85% of strokes are ischemic, while hemorrhagic stroke accounts for 15% of all strokes [2, 3]. Ischemic stroke is caused by cerebral artery occlusion [2]. Currently, intra-vascular thrombectomy and tissue plasminogen activator (tPA) are the only recognized methods for the treatment of ischemic stroke [4, 5]. However, tPA therapy is still limited by the narrow treatment window [6]. Therefore, it is necessary to find a new treatment strategy for ischemic stroke [7, 8]. Ischemic stroke involves a series of pathological processes, including ischemia, hypoxia, destruction of calcium homeostasis, free radical production, edema, and excitotoxicity [9–11]. Various subcellular organelles play roles in the pathogenesis of ischemic stroke. The dysregulation of calcium homeostasis can cause unfolded and misfolded proteins increased, resulting in endoplasmic reticulum (ER) stress [12, 13]. Golgi apparatus had obvious morphological changes in cerebral ischemia model [14]. Lysosomes are also involved in ischemic neuronal cell death, characterized by increased lysosomal enzyme activity [15]. In addition, mitochondria dysfunction plays a key role in the pathological course of ischemic stroke [16]. Intracerebral hemorrhage (ICH) refers to the primary, spontaneous, and nontraumatic hemorrhage occurring in the brain parenchyma [17]. At present, there is no effective treatment for ICH. Hematoma evacuation is used in some patients, but the effect is not satisfactory [18]. In addition to the primary injury caused by hematoma, secondary injury plays a vital role in the further injury of ICH [19]. The mechanism of secondary brain injury caused by ICH is very complex, which mainly involves the following aspects: inflammation, neuronal apoptosis and necrosis, oxidative stress, the generation of reactive oxygen species (ROS), mitochondrial function impaired and so on [20, 21]. Mitochondrial dysfunction may play an important role in pathophysiological process of intracerebral hemorrhage.

Mitochondria are extremely dynamic organelles, which involves constantly dividing and elongating [22]. Mitochondrial fission and fusion may be related to neuronal cell death [23]. Mitochondrial dynamics can not only maintain mitochondrial DNA integrity, oxidative respiratory chain and intracellular calcium signal transduction but is essential in
the process of apoptosis and neuronal death [24, 25]. Mitochondrial dysfunction is one of the markers of ischemia/reperfusion injury and subsequent neuronal death. Therefore, targeting the mitochondria is one of the strategies for the treatment of stroke [26]. In this review, we will discuss the role of mitochondria in stroke and focus on the effect of mitochondrial dynamin on the damage and recovery of neurons in stroke.

2. Mitochondrial Dysfunction in Stroke

2.1. Mitochondrial Dysfunction in Ischemic Stroke. Cerebral artery occlusion is the initial event of ischemic stroke, accompanied by severe oxygen and glucose deprivation (OGD) and a series of pathological processes, which eventually lead to irreversible cerebral injury and neuronal death [10, 27]. The initial loss of blood supply disrupts the neuronal functions and makes it unable to maintain normal transmembrane ion gradient, resulting in neuronal depolarization [9]. In the process of depolarization, neurons release glutamate, which leads to further depolarization of adjacent neurons [28]. Glutamate receptors, including N-methyl-D-aspartate-receptor (NMDAR), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR), and Kainic acid receptor (KAR), are overactivated, resulting in the influx and accumulation of Ca2+ into cells [29–31]. A large amount of Ca2+ influx leads to excessive production of ROS and mitochondrial dysfunction, including imbalance of mitochondrial fission and fusion, mitochondrial-induced apoptosis, and mitophagy [27]. Simultaneously, accumulation of intracellular Ca2+ results in the cleavage of Bcl-2 interaction domain into truncated bid [32], which interacts with proapoptotic proteins on the membrane of mitochondrial and thus causing the mitochondrial permeability transition pores (MPTP) opening [33]. MPTP opening leads to a decrease in mitochondrial membrane potential (Δψm), allows the release of cytochrome c or apoptosis-inducing factor (AIF) [34], and induces Ca2+ deregulation [35], thus leading to the activation of effector caspase and eventually the death of neurons [36, 37]. The imbalance of mitochondrial fission and fusion plays a vital role in neuronal death.

In addition to the adverse effects on neurons, ischemia-induced injury seriously affects glial cells, including oligodendrocytes, microglia, and astrocytes [38]. Neurons interact structurally with glial cells in the brain. Various types of glial cells play a vital role in regulating neuronal physiology and functions. Oligodendrocytes, myelin-forming cells in the central nervous system, are particularly sensitive to insults including hypoxia, reactive oxygen and nitrogen species and excitotoxicity [39, 40], which impair the functional activity of mitochondrial respiratory chain [41]. Microglia, macrophages in the brain, are critical for regulating neuroinflammation. Mitochondrial homeostasis plays an essential role in maintaining the function of microglia, and its imbalance is involved in the pathological process of ischemic stroke [42]. Several studies have demonstrated that excessive mitochondrial fission was observed in microglia during neuroinflammatory response [43, 44]. Astrocytes, the most abundant subtype of glial cells, are structural elements of gap junction and blood–brain barrier (BBB) and maintain multifaceted brain functions through communication with neurons [45]. Astrocytes protect neurons from hypoxia and excitotoxic injury [46, 47], while inhibiting astrocyte mitochondria function makes neurons susceptible to cell death [48]. Therefore, mitochondrial dysfunction plays an extremely important role in the pathogenesis of ischemic stroke.

2.2. Mitochondrial Dysfunction in Intracerebral Hemorrhage. The pathological process of ICH includes primary brain injury and secondary brain injury [21]. Secondary brain injury including elevated intracranial pressure or hydrocephalus may be the main factors leading to poor prognosis of ICH [49]. Mitochondrial dysfunction may impair the generation of adenosine triphosphate (ATP) and then lead to the failure of cellular pumps, resulting in cytoxic edema and neuronal death [50, 51]. Mitochondrial dysfunction leads to the destruction of ROS homeostasis, which further results in mitochondrial damage, and the vicious cycles continues [52]. Excessive ROS will break the balance between ROS and antioxidant system, which leads to DNA damage and lipid peroxidation, initiates apoptosis, and impairs the BBB, resulting in brain damage [53, 54]. It is reported that mitochondrial dynamic improvement can prevent neurologcal deficits after subarachnoid hemorrhage (SAH) [55, 56]. Therefore, protecting mitochondrial function may be a potential target for the treatment of hemorrhagic stroke injury [57].

3. The Role of Mitochondrial Dynamin

Mitochondria are dynamic organelles where homeostasis can be regulated by complicated processes, including fission and fusion, biogenesis, and elimination [58, 59]. Mitochondrial dynamics are regulated by many proteins (Table 1) [60]. Dynamin-related protein 1 (DRP1) and mitochondrial fission protein 1 (FIS1) are key regulators of fission, while mitofusin-1/2 (MFN1/MFN2) and optic atrophy 1 (OPA1) are key regulators of fusion [61–63]. Fusion of mitochondrial outer membranes is mediated by MFN1 and MFN2, while fusion of mitochondrial inner membrane is mediated by OPA1 [64]. Fission is responsible for isolating dysfunctional mitochondria that contain damaged proteins, unstable membranes, and damaged or mutated mitochondrial DNA [60, 65–68]. Fusion facilitates the complementation between neighboring mitochondria, enabling survival of damaged mitochondria [69]. Mitochondrial dynamics emerges as a crucial process in regulating cell survival and death. Mitochondrial fission precedes neuronal death after cerebral ischemic stroke [70–72]. In the review, we specifically focused on the role of mitochondrial dynamic protein in regulating the stability of mitochondrial internal environment in stroke.

4. Mitochondrial Fission Proteins and Stroke

4.1. DRP1. DRP1 is a highly conserved dynamin which is essential for mitochondrial biogenesis and maintenance of
| Mitochondria dynamics | Function | Proteins | Location | Modification | Reference |
|-----------------------|----------|----------|----------|--------------|-----------|
| Mitochondria fission  | Isolating dysfunctional mitochondria | DRP1 | Translocated from the cytoplasmic pool to the outer membrane of mitochondria during fission | S-nitroylation, SUMOylation, ubiquitination, and phosphorylation | [69, 73–79] |
|                      |          | FIS1     | Mitochondrial outer membrane | DRP1 recruitment factor, together with MFF, MID49, and MID51 | [80–83] |
| Mitochondria fusion  | Avoiding damage accumulation caused by mutations in mitochondrial DNA aging | MFN1/MFN2 | Mitochondrial outer membrane | Phosphorylation and ubiquitination | [63, 84–89] |
|                      |          | OPA1     | Mitochondrial inner membrane | Protease cleavage: L-OPA1 and S-OPA1 | [90–93] |

DRP1: dynamin-related protein 1; FIS1: fission protein 1; OPA1: optic atrophy 1; MFN1: mitofusin-1; MFN2: mitofusin-2; MFF: mitochondrial fission factor; MID49: mitochondrial dynamic proteins of 49 kDa; MID51: mitochondrial dynamics proteins of 51 kDa.
normal mitochondrial homeostasis and integrity [69]. DRP1 is recruited by FIS1, mitochondrial fission factor (MFF), and N-terminally anchored mitochondrial dynamic proteins of 49 and 51 kDa (MID49/51). Under normal conditions, DRP1 is translocated from the cytoplasmic pool to the outer membrane of mitochondria, where DRP1 is assembled into constrictive ring-like multimeric structures, and ultimately drives mitochondrial fission through a GTP-dependent mechanism [73–75]. However, different stress conditions, including oxidative stress and hypoxia, lead to up regulation of DRP1 expression, and increased translocation of cytosolic DRP1 to mitochondria, causing imbalance between mitochondrial fission and fusion, which results in mitochondrial disintegration and concomitant apoptosis [76, 77]. In addition, excessive fission is associated with a variety of neurodegenerative diseases, especially stroke [94].

Mitochondrial fission is the initial event of apoptotic cell death after ischemic stroke [70–72]. DRP1 mediated mitochondrial oxidative damage is involved in the pathological process of acute nerve injury induced by ICH [95]. Aberrant regulation of mitochondrial dynamics following stroke shifts the balance of mitochondrial fission and fusion towards fission, causing neuronal injury [42, 56]. DRP1, as the main mediator of mitochondrial fission, plays an important role in stroke. FIS1, MFF, and the proapoptotic Bcl-2 family protein Bax [96, 97] act directly or indirectly as DRP1 receptors to promote mitochondrial fission. DRP1 translocation and associated mitochondrial fission are key features of mitochondrial membrane potential (MMP) loss and neuronal cell death [98]. Several studies have reported that excessive mitochondrial fission in neurons is related to ischemic stroke, and inhibiting mitochondrial fission can reduce mitochondrial autophagy and neuronal apoptosis induced by ischemia/reperfusion injury [99].

4.1.1. Expression of DRP1 in Stroke. Abundant experimental evidence has demonstrated that the activation of DRP1 and mitochondrial fission contributes to cerebral ischemic injury. He et al. [100] have observed an increased level of DRP1 in mice subjected to cerebral ischemia and reperfusion injury. After the knockdown of DRP1, oxidative stress, mitochondrial ROS production, and the infarct volume are decreased, which contribute to the survival of neurons in cerebral ischemia. Antioxidants such as vitamin E or MitoQ can reduce DRP1 expression and mitochondrial fragments [101, 102]. DRP1 inhibitors can prevent OGD-induced death and glutamate excitotoxicity in primary cultured neurons, and reduce the infarct size in cerebral ischemia model in vivo [71]. Zhao et al. [72] showed that in middle cerebral artery occlusion (MCAO) mice, inhibition of DRP1 not only attenuates OGD induced cell death but also significantly reduces infarct size and neuronal death by inhibiting Bax insertion into the outer mitochondrial membrane and oligomerization and subsequent release of cytochrome c. Inhibition of DRP1 can prevent the morphological changes of mitochondria and subsequent cell death [71]. Inhibiting DRP1 by mdiv1 reduced ischemic injury, it paradoxically increased damage during reperfusion [103, 104]. Therefore, inhibition of DRP1 may be a potential therapeutic strategy for neurological diseases including ischemic stroke.

The DRP1 expression has been studied in hypoxia models of hyperglycemia, but results are controversial. Zuo et al. [105] revealed that hyperglycemia inhibit the level of DRP1 in cytoplasm and mitochondria, which caused the accumulation of damaged mitochondria and subsequent injury. Hyperglycemia altered self-adaptation by shifting permanent MCAO (pMCAO) induced morphological changes to fusion. And upregulation of DRP1 significantly reduced the infarct volume, decreased the release of cytochrome c, inhibit the activation of caspase-3, and reduced the production of ROS in hyperglycemia induced cerebral ischemia injury. It is suggested that DRP1 has protective effect on cerebral ischemia injury induced by hyperglycemia. Transient focal cerebral ischemia/reperfusion can upregulate DRP1, implicating that the dynamic imbalance of mitochondrial fission was involved in the mediating ischemic neuron injury. Paradoxically, Liu et al. [106] have demonstrated that diabetic hyperglycemia further aggravated the upregulation of DRP1 after MCAO, which indicate that diabetes further inclined mitochondrial dynamic to fission. The difference between these studies could be explained by the different ischemia times in the models. Zuo et al. used a permanent cerebral ischemia model and focused on the relationship between hyperglycemia after ischemia and mitochondrial homeostasis in the early stage of ischemia (within 6 h clinical treatment window of thrombolysis). However, Liu et al. emphasize on exploring the effect of hyperglycemia on cerebral ischemia/reperfusion injury. Notably, hyperglycemia is a well-known harmful factor in ischemic injury. Clinically, the intervention of blood glucose is expected to become a therapeutic target for cerebral ischemic injury aggravated by hyperglycemia.

There are some studies about the DRP1 expression level after ICH injury. The critical pathogenic factor of secondary injury after ICH, acrolein, causes increased mitochondrial DRP1 translocation and further excessive mitochondrial fission, while the acrolein scavenger significantly suppressed the expression of DRP1 and alleviated mitochondrial morphological damage after ICH, leading to significant amelioration of brain edema, neural apoptosis, and neurological deficits [95]. Therefore, excessive DRP1 activity may be an important pathogenic factor of ICH injury.

4.1.2. DRP1 Modification in Stroke. DRP1 is subjected to a variety of posttranscriptional modifications, including S-nitrosylation, SUMOylation, ubiquitination, and phosphorylation, which can activate or inhibit fission activity, and phosphorylation is the main modification [107, 108]. At present, four major phosphorylation sites of DRP1 have been found, which are located at serine residues 600, 616, 637, and 693 of DRP1 [78, 79, 109–111]. DRP1 phosphorylation at S616 facilitates mitochondrial fission, whereas DRP1 S637 and S693 phosphorylation inhibits it [110, 112] (Figure 1).

DRP1 Ser600 can be phosphorylated by protein kinase A (PKA), which can reduce the activity of DRP1 guanosine triphosphatase (GTPase) and decrease recruitment of DRP1 to
mitochondria [78, 113]. However, phosphorylation of the same serine residues by Ca\(^{2+}\)-calmodulin-dependent protein kinase I\(\alpha\) (CaMKI\(\alpha\)) resulted in significant increase in mitochondrial fission [109]. In addition, the phosphorylation of Ser616 can activate DRP1 and promote mitochondrial fission [114–117]. DRP1 at S616 can be phosphorylated by multiple kinases, including protein kinase Cd (PKCd), mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK)1/2, cyclin-dependent kinase 1 (CDK1)/cyclin B1, and calmodulin-dependent protein kinase II (CaMKII) [114, 115, 118].

The phosphate regulation of DRP1-S637 plays an essential role in determining ischemic sensitivity [119]. S637 is the inhibitory phosphorylation site of DRP1. Dephosphorylation of S637 can activate DRP1, promoting mitochondrial fission. As the first identified A-kinase anchoring protein (AKAP), AKAP1 can bind to the regulatory subunits of protein kinase A (PKA), which enables targeting of PKA holoenzyme to mitochondria [120, 121], and orchestrate coordinating the translational and posttranslational regulation of mitochondrial localization proteins. DRP1 is one of the key targets of AKAP1/PKA signaling complex. PKA mediates the phosphorylation of DRP1 at Serine 637 (S637 in human subtype 1 and S656 in rat subtype 1) and inhibits its fission activity [78, 113]. The outer mitochondrial AKAP1/PKA complex inhibits DRP1-dependent mitochondrial fission and protects neurons from ischemic stroke. AKAP1 is rapidly degraded following hypoxia [122–124], which impaired the inhibitory phosphorylation site S637 of DRP1 and enhanced mitochondrial localization of fission enzyme, promoting mitochondrial fission and the localization of DRP1 to mitochondria. However, deletion of AKAP1 did not alter overall level of DRP1. The neuron specific DRP1 activator, B\(\beta\)2, is a mitochondrial-localized protein phosphatase 2A (PP2A) regulatory subunit. Deletion of B\(\beta\)2 and maintenance of DRP1 Ser637 phosphorylation can improve mitochondrial respiratory capacity, maintain Ca\(^{2+}\) homeostasis, reduce superoxide production under ischemic and excitotoxic conditions, and rescue excessive stroke injury [94]. The phosphorylation regulation of DRP1-S693, which also inhibiting mitochondrial fission, plays an important role in ischemic stroke, and is related to the control of mitophagy induction [125]. As Chou et al. [110] revealed that DRP1 is phosphorylated by glycogen synthase kinase-3 beta (GSK3\(\beta\)) at Ser693, resulting in rapid elongation of mitochondria through attenuation of GTPase activity and
downregulation of cytochrome c release, caspases-3 and -7, which plays an anti-apoptotic role and alleviates ischemic injury.

In the pathological process of ICH injury, acrolein regulates the translocation of DRP1, which is partially dependent on ERK and AMP-activated protein kinase (AMPK) pathways, targeting DRP1 phosphorylation at Ser616 and Ser637, respectively [95]. Excessive DRP1-mediated fission will damage mitochondrial structure, resulting in impaired respiratory chain function, ATP deficiency, increased generation of mitochondrial ROS, and activation of apoptosis pathways [126, 127]. DRP1 inhibitor, mdivi-1, can ameliorate oxidative stress injury and neuronal apoptosis caused by subarachnoid hemorrhage [55, 128]. Several studies have shown that DRP1-mediated mitochondrial fission is usually accompanied by an intense inflammatory response [129]. The recruitment of DRP1 to mitochondria after ICH impairs mitochondrial morphology and astrocyte function, which can be rescued by adiponectin peptide, a crucial upstream regulator of DRP1, in vivo and in vitro [130]. Notably, when selective inhibition of AMPK pathway, a signal pathway regulating DRP1 phosphorylation at Ser637, it can be observed that adiponectin peptide-mediated protection against astrocytic inflammation and DRP1-mediated mitochondrial fission is inhibited [130]. The overexpression of tyrosine kinase Fyn participates in neuroinflammation, oxidative stress, and apoptosis, amplifies the up regulation of p-ser616 DRP1, and reduces the antiapoptotic protein induced by ICH, which can be reversed by mdivi-1 [131]. Therefore, phosphorylation at different sites regulated by kinases affects mitochondrial recruitment of DRP1, indicating different functional and morphological effects, and the regulation of DRP1 phosphorylation at different sites is a potential therapeutic target against the stroke injury.

4.1.3. DRP1 and Neuroinflammation. Neuroinflammation is one of the main causes of ischemic stroke, and reducing neuroinflammation can inhibit stroke-related injuries [132]. Neuroinflammation is accompanied by abnormal activation of JAK2/STAT3 pathway [133, 134]. DRP1 S616 appears to be associated with neuroinflammation. Anti-inflammatory drug atractylenolide III regulates neuroinflammation and improves ischemia/reperfusion injury by inhibiting JAK2/STAT3 pathway and reducing DRP1 translocation and phosphorylation at Ser616 to restrain mitochondrial fission [42]. Phosphorylated DRP1 can translocate to the outer membrane of mitochondria, where it interacts with FIS1 to induce mitochondrial fission, then producing ROS and activating nucleotide-binding domain- (NOD-) like receptor protein 3 (NLRP3) inflammasome [135]. Moreover, ketogenic diets (KD) may inhibit the mitochondrial translocation of DRP1 to suppress NLRP3 inflammasome activation, which may suppress ER stress and protect mitochondrial integrity, thus exerting neuroprotective effects in ischemic stroke [135].

4.1.4. DRP1 in Apoptosis and Autophagy. Multiple studies have reported that DRP1 translocation and increased mitochondrial fission are associated with apoptosis [96, 136, 137]. Inhibiting apoptosis can reduce ischemic injury [138]. Mitochondria can be degraded by mitophagy (selective) and bulk autophagy (nonselective), both of which may be caused by nutritional deficiency, starvation, or rapamycin treatment [139–141]. Autophagy is a process of degrading misfolded proteins and damaged organelles [142, 143]. Autophagy occurs in mitochondria and selectively removes damaged mitochondria, which is called mitophagy. Once disrupted, the damaged mitochondria would accumulate in the cellular, resulting in the release of a variety of mitochondrial proteins from the mitochondrial matrix to the cytoplasm, which leads to neuronal apoptosis. In some cases, mitophagy may be induced independently of bulk autophagy. In hyperglycemic animals, bulk autophagy increased and mitophagy decreased. Hyperglycemia elevated the autophagy level and maintained them at a high level after pMCAO. Since mitophagy can be induced by mitochondrial fission, inhibition of DRP1 can prevent the clearance of damaged mitochondria by mitophagy following pMCAO[104]. The harmful effect of blocking mitochondrial fission is due to the inhibition of mitophagy, which prevented the removal of damaged or defective mitochondria.

Over activation of DRP1 activity seems to be a crucial pathogenic factor of stroke injury. However, fragmented mitochondria are more likely to be eliminated by autophagosomes and then protecting cells from death [144]. In view of different disease models in different pathological processes, it is unclear whether DRP1-mediated mitochondrial fragmentation contributes to autophagy and neural survival after ICH. It is worth noting that autophagy may prevent the induction of apoptosis; however, excessive autophagy contributes to aggravate neural injury and induce apoptosis [145].

4.2. FIS1. FIS1 is the only DRP1 recruitment factor and can bind to human DRP1 in vitro [80]. When FIS1 is overexpressed, it can promote fission and participate in many fission dependent processes, including apoptosis and autophagy [81–83]. The deletion of FIS1 resulted in mitochondrial hyperfusion, mitochondrial dysfunction, and abnormal mitophagy [146]. FIS1 knockout could reduce mitochondrial autophagy [66]. In contrast to DRP1, there was no significant change in the expression of FIS1 in pMCAO or hyperglycemia model [105]. Paradoxically, one study showed that FIS1 decreased after ischemia/reperfusion, whereas hyperglycemia resulted in a distinct increase of FIS1 expression after 24h of reperfusion [147]. FIS1 knockout can reduce mitochondrial autophagy and respiration, reducing the number of mitochondria and activating apoptosis [66, 81].

5. Mitochondrial Fusion Proteins and Stroke

5.1. MFN1/MFN2. The fusion of outer membrane of mitochondria is mediated by MFN1 and MFN2. MFN1 and MFN2 have high homology (81%) and about 60% identity [84, 85]. MFN2 is a GTPase on the mitochondrial outer membrane, which is essential for maintaining intracellular homeostasis [63, 86]. MFN2 was proved to be involved in axonal transport of mitochondria [87], and it also...
participated in tethering ER to mitochondria [88]. Previous studies have demonstrated that MFN2 was crucial to mitochondrial oxidative phosphorylation: when MFN2 was deleted, mitochondrial oxidative phosphorylation was impaired and ATP production declined [89].

The MFN2 expression has been studied in ischemic stroke in recent years. Cultured primary rat cortical neurons subjected to excitotoxic doses of NMDA or exposed to OGD for 3 h showed reduced expression of MFN2 [148]. Likewise, a decrease in the MFN2 expression was also observed in middle cerebral artery occlusion in rats [147]. The expression of MFN2 decreased in C57BL/6 mice subjected to permanent middle cerebral artery occlusion for 12 or 24 h in vivo and in the hypoxia model of cohabit chloride simulating immortalized hippocampal neurons in vitro. However, hypoxia induced apoptosis was improved when MFN2 was restored by using lentivirus [149]. In mouse hippocampal HT22 cells, MFN2 decreased after 10 h of CoCl2 induced hypoxia injury, whereas MFN2 increased after 24 h of hypoxia, indicating that CoCl2 resulted in a transient decline of mitochondrial fusion [150]. OGD significantly reduced MFN2 in HT22 cells, but the expression of MFN1 did not change [151]. In normal and hyperglycemic ischemic animals, the deletion of mitochondrial uncoupling protein 2 (UCP2) significantly reduced the immunoreactivity of OPA1 and MFN2, indicating that the deletion of UCP2 inhibited mitochondrial fusion [100]. As one of the risk factors of ischemic stroke, hyperglycemia can aggravate ischemic brain injury and inhibit mitochondrial fusion. The change of the MFN2 expression in ischemic stroke may provide a research direction for the treatment of ischemic stroke.

When SAH occurs, the expression of Sirtuin3 (SIRT3), a NAD+ dependent deacetylase, was downregulated; however, SIRT3 agonist honokiol could increase the levels of MFN1 and MFN2, then maintaining mitochondrial morphology, protecting mitochondrial function, and alleviating brain edema and neurobehavioral defects [152]. Previous research implicated that SIRT3/AMPK is a positive feedback pathway [153]. The activation of AMPK pathway, which plays a key role in regulating cellular energy metabolism including mitochondrial biogenesis, glucose/fatty acid metabolism, and adaptive thermogenesis [154], can elevate the expression of both MFN1 and MFN2 [155]. However, the treatment of an AMPK inhibitor, compound C, can eliminate the protective effect of honokiol on mitochondrial morphology [152]. All of these demonstrated that the activation of SIRT3/AMPK pathway is favor to the protective response of honokiol on mitochondrial fusion in SAH.

The expression of MFN2 in stroke involves a variety of molecular mechanisms. Downregulation of MFN2 leads to mitochondrial dysfunction, ER stress, destruction of calcium homeostasis, and oxidative stress and enhanced the translocation of Bax to mitochondria [156–158], causing delayed neuronal death [159]. The absence of MFN2, which has been demonstrated to stimulate Bax oligomerization, promotes outer mitochondrial membrane remodeling by DRP1 [97]. Changes in MFN2 level facilitates Bax assembly and induces mitochondrial outer membrane permeabilization by affecting the equilibrium of interactions between pro and antiapoptotic different members of the Bcl-2 family [160]. In addition, MFN2 interacts with NLRP3 through its hydrophobic heptad repeat region to promote NLRP3 to recruit IL-1β secretion [161]. Knockdown of MFN2 decreased NLRP3-dependent caspase-1 activation and production of IL-1β [161]. MFN2 has been shown to have antiapoptotic effect and its expression is reduced under hypoxia [149, 162]. Inhibiting mitochondrial fusion promotes apoptosis. Bak and Bax, members of Bcl-2 protein family, regulate mitochondrial fusion rate by interacting with MFN2 and thus maintain normal mitochondrial morphology [163–166]. The loss of MFN2 contributes to the enhancement of ischemia/reperfusion injury [167]. In addition, MFN2 can influence mitochondrial morphology and participate in mitochondrial autophagy. PINK1–Parkin can ubiquitinate MFN2, and the biological effect can be amplified by phosphorylated MFN2 [168]. Ubiquitinated MFN2 inhibits mitochondrial fusion via increased proteasome degradation, leading to mitochondrial fragmentation and promoting mitochondrial autophagy. PKA inhibition rescued mitochondrial morphology and facilitated optic nerve head astrocyte survival via increasing the oligomerization of MFN1/ MFN2 against oxidative stress accompanied by cyclic adenosine monophosphate (cAMP) elevation [169]. There is evidence that MFN2 activation may protect organelles against permeability transition that is closely associated with programmed cell death, interfere with Bax activation, reduce the susceptibility to free radical induced depolarization, and thus play a neuroprotective role in stroke injury [170]. Understanding the molecular mechanism of MFN2 in stroke may contribute to have a deeper insight on pathological process of stroke and provides some therapeutic targets for the treatment of stroke.

5.2. OPA1. OPA1 mediates the fusion of mitochondria inner membrane. OPA1 belongs to the dynamin family and has three conserved domains: a GTPase domain, an intermediate domain, and a carboxyl terminal coil domain also known as GTPase effector domain [90]. Different from other dynamins, OPA1 has a variety of isoforms, which must be processed from long membrane anchored form (L-OPA1) to short soluble form (S-OPA1) via protease cleavage to achieve effective fusion of mitochondrial inner membrane [91]. S-OPA1 cannot trigger the fusion of mitochondrial inner membrane alone but rather must cooperate with L-OPA1 [92, 93]. S-OPA1 promotes membrane fusion by oligomerization with L-OPA1, which supports the hydrolsis of GTP and the conformational change of L-OPA1 [91].

There is substantial evidence that the expression of OPA1 decreases after hypoxia injury [150], which is also observed after ischemia/reperfusion injury in vivo [171]. Cerebral ischemia inhibited the expression of OPA1 at 24 h and 72 h and suppressed MFN2 at 6–72 h of recovery in vivo [172]. Moreover, the expression of OPA1 further reduced under hyperglycemia [106]. The depletion or knockdown of OPA1 leads to mitochondrial rupture, cristae structure disorder, and the initiation of apoptosis [173–175]. In addition, the deletion of UCP2 further reduced the level
of OPA1, inclining the dynamic balance of mitochondria to fusion [100]. The loss of OPA1 function via silencing, gene knock-out, and dominant-negative isoform expression leads to an inhibition of fusion, subsequent the upregulating of mitochondria fission, and increased susceptibility to cell death induction [176]. Importantly, it has been reported that the control of transgenic overexpression of OPA1 can “tighten” the cristae junction, limit the release of cytochrome c, and provide protection against ischemic brain injury after stroke [177]. Together, all studies suggest that OPA1 is a potential target for treatment of ischemic stroke.

Consistently, mitochondrial dynamics tends to mitochondrial fission accompanied by mitochondrial fragmentation, and the expression of OPA1 decreased after SAH [178, 179]. Epigallocatechin-3-gallate (EGCG), a bioactive polyphenol compound with antioxidant activity, can induce normal autophagy flux at the initiation and formation stages via regulating autophagy related 5 (ATG5) and beclin-1 to as to eliminate damaged mitochondria timely, and downregulate calcium concentration to regulate the expression of mitochondrial fission and fusion genes to balance mitochondrial dynamics [179]. Therefore, maintaining the balance of mitochondrial fission and fusion cycle and activating autophagy has therapeutic significance for SAH.

OPA1 plays an important role in stroke. OPA1 can attenuate cerebral edema after ischemic stroke [180]. Similarly, enhancing the expression of OPA1 plays a neuroprotective role in SAH injury [56]. OPA1 has two known functions: maintaining cristae junction and mitochondrial fusion. The induction of neuronal death is mediated by the release of cytochrome c from mitochondria, which is controlled by cristae junctions gated by OPA1 oligomer [176]. Blocking the expression of OPA1 by siRNA resulted in the morphological changes of mitochondrial cristae and the production of vesicle structure [181]. OPA1 is also vital for the assembly and stabilization of mitochondrial respiratory chain and the isolation of proapoptotic cytochrome molecules in these tight junctions [177]. Inhibition or mutation of OPA1 results in impaired mitochondrial function, fragmentation, cytochrome c release, cristae remodeling, and apoptosis [172, 174]. Exercise preconditioning can alleviate the brain edema and improve the neurological deficits after ischemic stroke through facilitating the expression of OPA1 and mitochondrial complex II/III/IV closely related to ATP generation [180]. After SAH, MitoQ (a mitochondrial-targeting drug) can promote the attenuation of BBB destruction and the improvement of related neurological deficit via NF-E2-related factor 2 (Nrf2)/prohibitin 2 (PHB2)/OPA1 pathway [178]. Therefore, maintaining the integrity of mitochondrial morphology is an important therapeutic target for stroke (Figure 2).

### 6. Mitochondria Dysfunction, ER Stress, and Ca^{2+} in Stroke

Mitochondria are the repository of calcium, keeping the levels of cytosolic calcium low [182]. ER is a critical organelle that stores and releases Ca^{2+}, involved in the
maintenance of Ca\textsuperscript{2+} homeostasis [183]. Calcium overload is one of the important pathological mechanisms of cell death caused by stroke [184]. Under severe stress conditions including stroke, excessive accumulation of intracellular Ca\textsuperscript{2+} can lead to the massive release of glutamate, mitochondrial dysfunction, ER stress, neuronal apoptosis, and cell death [185, 186].

After stroke, mitochondrial dysfunction, accompanied by increased ROS production, can cause ER stress, followed by the release of Ca\textsuperscript{2+} from ER into the cytoplasm [187, 188]. The increased free Ca\textsuperscript{2+} in the cytoplasm is transported to the mitochondrial matrix by the Ca\textsuperscript{2+} uniporter. The dysregulation of Ca\textsuperscript{2+} level induces the formation of MPTP, allowing the penetration of toxic mitochondrial matrix molecules into the cytoplasm and eventually causing apoptosis [189]. Disturbance of Ca\textsuperscript{2+} homeostasis can cause neuronal cell damage in stroke [190]; so, maintaining Ca\textsuperscript{2+} homeostasis may be a potential therapeutic target for poststroke neuroprotection. It was demonstrated that transient receptor potential melastatin 2 (TRPM2), a nonselective cation channel with calcium permeability, can be activated under oxidative stress, increasing calcium concentration, which was detrimental in cerebral ischemic stroke [191–194]. The inhibition of endogenous TRPM2 can suppress Ca\textsuperscript{2+} influx and subsequently cell death induced by ischemic stroke in vivo and in vitro [195–198]. Ischemic preconditioning can induce store-operated calcium entry (SOCE) and the release of Ca\textsuperscript{2+}, preventing the downregulation of stromal interacting molecule 1 (STIM1) and calcium-release-activated-calcium channel protein 1 (ORAI1) induced by ischemia-reperfusion injury and restoring the Ca\textsuperscript{2+} homeostasis of ER, thereby playing a neuroprotective role [199].

Ca\textsuperscript{2+} is one of the vital signals of the interaction between ER and mitochondria [200, 201]. Mitochondria and Ca\textsuperscript{2+} mutually regulate each other. Maintaining calcium homeostasis is essential for the balance of mitochondrial dynamics [202].

7. Conclusions and Challenges

Mitochondrial dysfunction is the initial event of stroke. Mitochondria are involved in the pathology of stroke by inducing oxidative stress, elevating ROS generation, impairing calcium homeostasis, and controlling cell death. The maintenance of the mitochondria function largely depends on the balance of mitochondrial dynamics. The imbalance of mitochondrial fission and fusion after stroke may increase mitochondrial fragmentation, cause aberrant mitochondrial morphology and disruption of mitochondrial homeostasis, and thus eventually trigger neuronal death. Proper control of mitochondrial fission and fusion is essential for maintaining mitochondrial function and overall cellular health. The clinical treatment of stroke is still a great challenge. Targeting mitochondrial dynamics and regulating the expression of mitochondrial dynamin seem to provide a therapeutic basis for stroke. Therefore, understanding the changes of mitochondrial fission and fusion protein in stroke and the intervention mechanism can provide a new research direction for the prevention and treatment of stroke. However, the discovery of mitochondrial dynamics targeted drugs is still an important challenge for stroke research. The search for new drugs that can improve the clinical prognosis of stroke also needs to be further explored.

Conflicts of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Authors’ Contributions

CL and LZ conceived, organized, and discussed the work. CL contributed to manuscript writing and literature search. CC, HQ, CA, JC, JT, and LZ revised the manuscript. All authors contributed to the review and approved the submitted version.

Acknowledgments

This work has been supported by the National Natural Science Foundation of China (Grant nos. 81771423 and 81974212) and Natural Science Foundation of Hunan Province (Grant no. 2020JJ4822).

References

[1] P. Amarenco, J. Bogousslavsky, L. R. Caplan, G. A. Donnan, and M. G. Hennerici, “Classification of stroke subtypes,” Cerebrovascular Diseases, vol. 27, no. 5, pp. 493–501, 2009.
[2] P. A. Lapcak and J. H. Zhang, “The high cost of stroke and stroke cytoprotection research,” Translational Stroke Research, vol. 8, no. 4, pp. 307–317, 2017.
[3] C. C. Beal, “Gender and stroke symptoms: a review of the current literature,” The Journal of Neuroscience Nursing, vol. 42, no. 2, pp. 80–87, 2010.
[4] A. P. Jadhav and T. G. Jovin, “Endovascular therapy for acute ischemic stroke: the standard of care;” Brain Circulation, vol. 2, no. 4, pp. 178–182, 2016.
[5] S. Yoshimura, N. Sakai, K. Uchida et al., “Endovascular therapy in ischemic stroke with acute large-vessel occlusion: recovery by endovascular salvage for cerebral ultra-acute embolism Japan registry 2,” Journal of the American Heart Association, vol. 7, no. 9, 2018.
[6] B. Diop-Frimpong, V. P. Chauhan, S. Krane, Y. Boucher, and R. K. Jain, “Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 7, pp. 2909–2914, 2011.
[7] C. Xing, K. Hayakawa, and E. H. Lo, “Mechanisms, imaging, and therapy in stroke recovery,” Translational Stroke Research, vol. 8, no. 1, pp. 1–2, 2017.
[8] S. H. Yang, M. Lou, B. Luo, W. J. Jiang, and R. Liu, “Precision medicine for ischemic stroke, let us move beyond time is brain,” Translational Stroke Research, vol. 9, no. 2, pp. 93–95, 2018.
[9] S. E. Khoshnam, W. Winlow, M. Farzaneh, Y. Farbood, and H. F. Moghaddam, “Pathogenic mechanisms following
ischemic stroke,” *Neurological Sciences*, vol. 38, no. 7, pp. 1167–1186, 2017.

[10] S. E. Khoshnam, W. Winlow, and M. Farzaneh, “The interplay of MicroRNAs in the inflammatory mechanisms following ischemic stroke,” *Journal of Neuropathology and Experimental Neurology*, vol. 76, no. 7, pp. 548–561, 2017.

[11] H. B. Van Der Worp, M. R. Macleod, and R. Kollmar, “Therapeutic hypothermia for acute ischemic stroke: ready to start large randomized trials?,” *Journal of Cerebral Blood Flow and Metabolism*, vol. 30, no. 6, pp. 1079–1093, 2010.

[12] M. W. Greve and B. J. Zink, “Pathophysiology of traumatic brain injury,” *Mount Sinai Journal of Medicine*, vol. 76, no. 2, pp. 97–104, 2009.

[13] G. Begum, H. Q. Yan, L. Li, A. Singh, C. E. Dixon, and D. Sun, “Docosahexaenoic acid reduces ER stress and abnormal protein accumulation and improves neuronal function following traumatic brain injury,” *The Journal of Neuroscience*, vol. 34, no. 10, pp. 3743–3755, 2014.

[14] F. Zhao, T. Kuroiwa, N. Miyasaka et al., “Ultrastructural and MRI study of the substantia nigra evolving exofocal post-ischemic neuronal death in the rat,” *Neuropathology*, vol. 22, no. 3, pp. 91–105, 2002.

[15] H. Iglek, S. Iglek, G. Güner, and N. Özdamar, “Evaluation of lipid peroxidation, cathepsin L and acid phosphatase activities in experimental brain ischemia-reperfusion,” *Brain Research*, vol. 843, no. 1-2, pp. 18–24, 1999.

[16] K. Abe, M. Aoki, J. Kawagoe et al., “Ischemic delayed neuronal death,” *Stroke*, vol. 26, no. 8, pp. 1478–1489, 1995.

[17] A. Morotti and J. N. Goldstein, “Diagnosis and management of acute intracerebral hemorrhage,” *Emergency Medicine Clinics of North America*, vol. 34, no. 4, pp. 883–899, 2016.

[18] A. D. Mendelow, B. A. Gregson, E. N. Rowan et al., “Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II): a randomised trial,” *Lancet*, vol. 382, no. 9890, pp. 397–408, 2013.

[19] R. F. Keep, Y. Hua, and G. Xi, “Intracerebral haemorrhage: mechanisms of injury and therapeutic targets,” *Lancet Neurology*, vol. 11, no. 8, pp. 720–731, 2012.

[20] S. Chen, Q. Yang, G. Chen, and J. H. Zhang, “An update on inflammation in the acute phase of intracerebral hemorrhage,” *Translational Stroke Research*, vol. 6, no. 1, pp. 4–8, 2015.

[21] Z. Wang, F. Zhou, Y. Dou et al., “Melatonin alleviates intracerebral hemorrhage-induced secondary brain injury in rats via suppressing apoptosis, inflammation, oxidative stress, DNA damage, and mitochondria injury,” *Translational Stroke Research*, vol. 9, no. 1, pp. 74–91, 2018.

[22] A. J. Valente, L. A. Maddalena, E. L. Robb, F. Moradi, and J. A. Stuart, “A simple ImageJ macro tool for analyzing mitochondrial network morphology in mammalian cell culture,” *Acta Histochemica*, vol. 119, no. 3, pp. 315–326, 2017.

[23] E. Bossy-Wetzel, M. J. Barsoum, A. Godzik, R. Schwarzenbacher, and S. A. Lipton, “Mitochondrial fission in apoptosis, neurodegeneration and aging,” *Current Opinion in Cell Biology*, vol. 15, no. 6, pp. 706–716, 2003.

[24] G. Twigg and O. S. Shirihai, “The interplay between mitochondrial dynamics and mitophagy,” *Antioxidants & Redox Signaling*, vol. 14, no. 10, pp. 1939–1951, 2011.

[25] L. Calo, Y. Dong, R. Kumar, K. Przyklenk, and T. Sanderson, “Mitochondrial dynamics: an emerging paradigm in ischemia-reperfusion injury,” *Current Pharmaceutical Design*, vol. 19, no. 39, pp. 6848–6857, 2013.

[26] Q. Hu, J.-l. Huang, A. Manaenko, Z.-h. Ye, and X.-j. Sun, “Hypoxia therapy—a new hope for the treatment of mitochondrial dysfunctions,” *Medical Gas Research*, vol. 6, no. 3, pp. 174–176, 2016.

[27] Z. He, N. Ning, Q. Zhou, S. E. Khoshnam, and M. Farzaneh, “Mitochondria as a therapeutic target for ischemic stroke,” *Free Radical Biology & Medicine*, vol. 146, p. 45, 2020.

[28] S. S. Andrabi, S. Parvez, and H. Tabassum, “Ischemic stroke and mitochondria: mechanisms and targets,” *Protoplasma*, vol. 257, no. 2, pp. 335–343, 2020.

[29] E. Berdichevsky, N. Riveros, S. Sánchez-Armáss, and F. Orrego, “Kainate, N-methylaspartate and other excitatory amino acids increase calcium influx into rat brain cortex cells in vitro,” *Neuroscience Letters*, vol. 36, no. 1, pp. 75–80, 1983.

[30] B. Liu, M. Liao, J. G. Mielke et al., “Ischemic insults directly glutamate receptor subunit 2-lacking AMPA receptors to synaptic sites,” *The Journal of Neuroscience*, vol. 26, no. 20, pp. 5309–5319, 2006.

[31] P. L. Peng, X. Zhong, W. Tu et al., “ADAR2-dependent RNA editing of AMPA receptor subunit GluR2 determines vulnerability of neurons in forebrain ischemia,” *Neuron*, vol. 49, no. 5, pp. 719–733, 2006.

[32] V. Nikoletopoulou, M. Markaki, K. Palikaras, and N. Tavernarakis, “Crosstalk between apoptosis, necrosis and autophagy,” *Biochimica et Biophysica Acta*, vol. 1833, no. 12, pp. 3448–3459, 2013.

[33] M. J. Pérez and R. A. Quintanilla, “Development or disease: duality of the mitochondrial permeability transition pore,” *Developmental Biology*, vol. 426, no. 1, pp. 1–7, 2017.

[34] C. Culmsee, C. Zhu, S. Landshamer et al., “Apoptosis-inducing factor triggered by poly(ADP-ribose) polymerase and bid mediates neuronal cell death after oxygen-glucose deprivation and focal cerebral ischemia,” *The Journal of Neuroscience*, vol. 25, no. 44, pp. 10262–10272, 2005.

[35] M. W. Ward, A. C. Rego, B. G. Frenguelli, and D. G. Nicholls, “Mitochondrial membrane potential and glutamate excitotoxicity in cultured cerebellar granule cells,” *The Journal of Neuroscience*, vol. 20, no. 19, pp. 7208–7219, 2000.

[36] F. Liu, J. Lu, A. Manaenko, J. Tang, and Q. Hu, “Mitochondria in ischemic stroke: new insight and implications,” *Aging and Disease*, vol. 9, no. 5, pp. 924–937, 2018.

[37] J. L. Yang, S. Mukda, and S. D. Chen, “Diverse roles of mitochondria in ischemic stroke,” *Redox Biology*, vol. 16, pp. 263–275, 2018.

[38] F. E. Song, J. L. Huang, S. H. Lin, S. Wang, G. F. Ma, and X. P. Tong, “Roles of NG2-glia in ischemic stroke,” *CNS Neurosci & Therapeutics*, vol. 23, no. 7, pp. 547–553, 2017.

[39] J. E. Merrill and N. J. Scolding, “Mechanisms of damage to myelin and oligodendrocytes and their relevance to disease,” *Neuropathology and Applied Neurobiology*, vol. 25, no. 6, pp. 435–458, 1999.

[40] K. J. Smith, R. Kapoor, and P. A. Felts, “Demyelination: The Role of Reactive Oxygen and Nitrogen Species,” *Brain Pathology*, vol. 9, no. 1, pp. 69–92, 1999.

[41] I. Ziaibrez, G. Campbell, J. Rist et al., “Injury and differentiation following inhibition of mitochondrial respiratory chain complex IV in rat oligodendrocytes,” *Glia*, vol. 58, no. 15, pp. 1827–1837, 2010.
[42] K. Zhou, J. Chen, J. Wu et al., "Atractylenolide III ameliorates cerebral ischemic injury and neuroinflammation associated with inhibiting JAK2/STAT3/Drp1-dependent mitochondrial fission in microglia," *Phytochemistry*, vol. 59, p. 152922, 2019.

[43] J. Park, H. Choi, B. Kim et al., "Peroxiredoxin 5 (Prx5) decreases LPS-induced microglial activation through regulation of Ca2+/calcinineurin-Drp1-dependent mitochondrial fission," *Free Radical Biology & Medicine*, vol. 99, pp. 392–404, 2016.

[44] M. Katoh, B. Wu, H. B. Nguyen et al., "Mitochondrial fission and fusion modifies phenotypes of microglia in neuroinflammation," *Scientific Reports*, vol. 7, no. 1, p. 4942, 2017.

[45] G. E. Barreto, J. Gonzalez, Y. Torres, and L. Morales, "Astrocyte-neuronal crosstalk: implications for neuroprotection from brain injury," *Neuroscience Research*, vol. 71, no. 2, pp. 107–113, 2011.

[46] Y.-B. Ouyang, L. Xu, Y. Lu et al., "Astrocyte-enriched miR-29a targets PUMA and reduces neuronal vulnerability to forebrain ischemia," *Glia*, vol. 61, no. 11, pp. 1784–1794, 2013.

[47] X. F. Wang and M. S. Cynader, "Pyruvate released by astrocytes protects neurons from copper-catalyzed cysteine neurotoxicity," *The Journal of Neuroscience*, vol. 21, no. 10, pp. 3322–3331, 2001.

[48] L. A. Voloboueva, S. W. Suh, R. A. Swanson, and R. G. Giffard, "Inhibition of mitochondrial function in astrocytes: implications for neuroprotection," *Journal of Neurochemistry*, vol. 102, no. 4, pp. 1383–1394, 2007.

[49] S. B. Murthy, Y. Moradiya, J. Dawson et al., "Perihematomal edema and functional outcomes in intracerebral hemorrhage: influence of hematoma volume and location," *Stroke*, vol. 46, no. 11, pp. 3088–3092, 2015.

[50] J. Sook Kim-Han, S. J. Kopp, L. L. Dugan, and M. N. Diringer, "Perihematomal mitochondrial dysfunction after intracerebral hemorrhage," *Stroke*, vol. 37, no. 10, pp. 2457–2462, 2006.

[51] H. Prentice, J. P. Modi, and J. Y. Wu, "Mechanisms of neuronal protection against excitotoxicity, endoplasmic reticulum stress, and mitochondrial dysfunction in stroke and neurodegenerative diseases," *Oxidative Medicine and Cellular Longevity*, vol. 2015, Article ID 964518, 7 pages, 2015.

[52] A. S. Brunswick, B. Y. Hwang, G. Appelboom, R. Y. Hwang, M. A. Piazza, and E. S. Connolly, "Serum biomarkers of spontaneous intracerebral hemorrhage induced secondary brain injury," *Journal of the Neurological Sciences*, vol. 321, no. 1-2, pp. 1–10, 2012.

[53] N. Han, S.-J. Ding, T. Wu, and Y.-L. Zhu, "Correlation of free radical level and apoptosis after intracerebral hemorrhage in rats," *Neuroscience Bulletin*, vol. 24, no. 6, pp. 351–358, 2008.

[54] M. Katsu, K. Niizuma, H. Yoshioka, N. Okami, H. Sakata, and P. H. Chan, "Hemoglobin-induced oxidative stress contributes to matrix metalloproteinase activation and blood-brain barrier dysfunction in vivo," *Journal of Cerebral Blood Flow and Metabolism*, vol. 30, no. 12, pp. 1939–1950, 2010.

[55] P. Wu, Y. Li, S. Zhu et al., "Mdivi-1 alleviates early brain injury after experimental subarachnoid hemorrhage in rats, possibly via inhibition of Drp1-activated mitochondrial fission and oxidative stress," *Neurochemical Research*, vol. 42, no. 5, pp. 1449–1458, 2017.

[56] T. Zhang, P. Wu, J. H. Zhang et al., "Docosahexaenoic acid alleviates oxidative stress-based apoptosis via improving mitochondrial dynamics in early brain injury after subarachnoid hemorrhage," *Cellular and Molecular Neurobiology*, vol. 38, no. 7, pp. 1413–1423, 2018.

[57] J. Zheng, L. Shi, F. Liang et al., "Sirt3 ameliorates oxidative stress and mitochondrial dysfunction after intracerebral hemorrhage in diabetic rats," *Frontiers in Neuroscience*, vol. 12, p. 414, 2018.

[58] F. Legros, A. Lombès, P. Frachon, and M. Rojo, "Mitochondrial fusion in human cells is efficient, requires the inner membrane potential, and is mediated by mitofusins," *Molecular Biology of the Cell*, vol. 13, no. 12, pp. 4343–4354, 2002.

[59] W. Bleazard, J. M. McCaffery, E. J. King et al., "The dynamin-related GTPase Dnm1 regulates mitochondrial fission in yeast," *Nature Cell Biology*, vol. 1, no. 5, pp. 298–304, 1999.

[60] S. Hoppins, L. Lackner, and J. Nunnari, "The machines that divide and fuse mitochondria," *Annual Review of Biochemistry*, vol. 76, pp. 751–780, 2007.

[61] F. Rodius, T. Claudepierre, H. Rosas-Vargas et al., "Dystrophins in developing retina: Dp260 expression correlates with synaptic maturation," *Neuroreport*, vol. 8, no. 9-10, pp. 2383–2387, 1997.

[62] C. Alexander, M. Votruba, U. E. A. Pesch et al., "OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28," *Nature Genetics*, vol. 26, no. 2, pp. 211–215, 2000.

[63] H. Chen, S. A. Detmer, A. J. Ewald, E. E. Griffin, S. E. Fraser, and D. C. Chan, "Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development," *The Journal of Cell Biology*, vol. 160, no. 2, pp. 189–200, 2003.

[64] B. Westermann, "Mitochondrial fusion and fission in cell life and death," *Nature Reviews. Molecular Cell Biology*, vol. 11, no. 12, pp. 872–884, 2010.

[65] G. Twig, B. Hyde, and O. S. Shirihi, "Mitochondrial fusion, fission and autophagy as a quality control axis: the bioenergetic view," *Biochimica et Biophysica Acta*, vol. 1777, no. 9, pp. 1092–1097, 2008.

[66] L. C. Gomes and L. Scorrano, "High levels of Fis1, a profission mitochondrial protein, trigger autophagy," *Biochimica et Biophysica Acta*, vol. 1777, no. 7-8, pp. 860–866, 2008.

[67] A. Malena, E. Loro, M. Di Re, I. J. Holt, and L. Vergani, "Inhibition of mitochondrial fission favours mutant over wild-type mitochondrial DNA," *Human Molecular Genetics*, vol. 18, no. 18, pp. 3407–3416, 2009.

[68] D. F. Suen, D. P. Narendra, A. Tanaka, G. Manfredi, and R. J. Youle, "Parkin overexpression selects against a deleterious mtDNA mutation in heteroplasmic cybrid cells," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 26, pp. 11835–11840, 2010.

[69] R. J. Youle and A. M. Van Der Bliek, "Mitochondrial fission, fusion, and stress," *Science*, vol. 337, no. 6098, pp. 1062–1065, 2012.

[70] M. J. Barsoum, H. Yuan, A. A. Gerencser et al., "Nitric oxide-induced mitochondrial fission is regulated by dynamin-related GTPases in neurons," *The EMBO Journal*, vol. 25, no. 16, pp. 3900–3911, 2006.

[71] J. Grohm, S. W. Kim, U. Mamrak et al., "Inhibition of Drp1 provides neuroprotection in vitro and in vivo," *Cell Death and Differentiation*, vol. 19, no. 9, pp. 1446–1458, 2012.
[72] Y.-X. Zhao, M. Cui, S.-F. Chen, Q. Dong, and X.-Y. Liu, “Amelioration of Ischemic Mitochondrial Injury and Bax-Dependent Outer Membrane Permeabilization by Mdivi-1,” CNS Neuroscience & Therapeutics, vol. 20, no. 6, pp. 528–538, 2014.

[73] H. Chen and D. C. Chan, “Mitochondrial dynamics in regulating the unique phenotypes of cancer and stem cells,” Cell Metabolism, vol. 26, no. 1, pp. 39–48, 2017.

[74] F. Kraus and M. T. Ryan, “The constriction and scission machineries involved in mitochondrial fission,” Journal of Cell Science, vol. 130, no. 18, pp. 2953–2960, 2017.

[75] R. Kalia, R. Y.-R. Wang, A. Yusuf et al., “Structural basis of mitochondrial receptor binding and constriction by DRP1,” Nature, vol. 558, no. 7710, pp. 401–405, 2018.

[76] H. Pradeep, B. Sharma, and G. K. Rajanikant, “Drp1 in ischemic neuronal death: an unusual suspect,” Current Medicinal Chemistry, vol. 21, no. 19, pp. 2183–2189, 2014.

[77] S. Wu, F. Zhou, Z. Zhang, and D. Xing, “Mitochondrial oxidative stress causes mitochondrial fragmentation via differential modulation of mitochondrial fission–fusion proteins,” The FEBS Journal, vol. 278, no. 6, pp. 941–954, 2011.

[78] C. R. Chang and C. Blackstone, “Cyclic AMP-dependent protein kinase phosphorylation of Drp1 regulates Its GTPase activity and mitochondrial morphology,” The Journal of Biological Chemistry, vol. 282, no. 30, pp. 21583–21587, 2007.

[79] T. Bo, T. Yamamori, M. Suzuki, Y. Sakai, K. Yamamoto, and O. Inanami, “Calmodulin-dependent protein kinase II (CaM-KII) mediates radiation-induced mitochondrial fission by regulating the phosphorylation of dynamin-related protein 1 (Drp1) at serine 616,” Biochemical and Biophysical Research Communications, vol. 495, no. 2, pp. 1601–1607, 2018.

[80] Q. Shen, K. Yamano, B. P. Head et al., “Mutations in Fis1 disrupt orderly disposal of defective mitochondria,” Molecular Biology of the Cell, vol. 25, no. 1, pp. 145–159, 2014.

[81] G. Twig, A. Elorza, A. J. Molina et al., “Fission and selective fusion govern mitochondrial segregation and elimination by autophagy,” The EMBO Journal, vol. 27, no. 2, pp. 433–446, 2008.

[82] A. Jofuku, N. Ishihara, and K. Mihara, “Analysis of functional domains of rat mitochondrial Fis1, the mitochondrial fission-stimulating protein,” Biochemical and Biophysical Research Communications, vol. 333, no. 2, pp. 650–659, 2005.

[83] D. I. James, P. A. Parone, Y. Mattenberger, and J.-C. Martinou, “bFis1, a novel component of the mammalian mitochondrial fission machinery,” The Journal of Biological Chemistry, vol. 278, no. 38, pp. 36373–36379, 2003.

[84] O. M. De Brito and L. Scorrano, “Mitofusin 2: a mitochondria-shaping protein with signaling roles beyond fusion,” Antioxidants & Redox Signaling, vol. 10, no. 3, pp. 621–634, 2008.

[85] M. Liepa, M. Palacin, and A. Zorzano, “Mitochondrial dynamics in mammalian health and disease,” Physiological Reviews, vol. 89, no. 3, pp. 799–845, 2009.

[86] H. Chen, A. Chomyn, and D. C. Chan, “Disruption of fusion results in mitochondrial heterogeneity and dysfunction,” The Journal of Biological Chemistry, vol. 280, no. 28, pp. 26185–26192, 2005.

[87] A. Misko, S. Jiang, I. Wergorzewska, J. Milbrandt, and R. H. Baloh, “Mitofusin 2 is necessary for transport of axonal mitochondria and interacts with the Miro/Milton complex,” The Journal of Neuroscience, vol. 30, no. 12, pp. 4232–4240, 2010.

[88] O. M. De Brito and L. Scorrano, “Mitofusin 2 tethers endoplasmic reticulum to mitochondria,” Nature, vol. 456, no. 7222, pp. 605–610, 2008.

[89] A. G. Rocha, A. Franco, A. M. Krezeld et al., “MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-tooth disease type 2A,” Science, vol. 360, no. 6386, pp. 336–341, 2018.

[90] A. Zerem, K. Yosovich, Y. C. Rappaport et al., “Metabolic stroke in a patient with bi-allelic OPA1 mutations,” Metabolic Brain Disease, vol. 34, no. 4, pp. 1043–1048, 2019.

[91] D. Zhang, Y. Zhang, J. Ma et al., “Cryo-EM structures of S-OPA1 reveal its interactions with membrane and changes upon nucleotide binding,” eLife, vol. 9, 2020.

[92] T. Ban, T. Ishihara, H. Kohno et al., “Molecular basis of selective mitochondrial fusion by heterotypic action between OPA1 and cardiolipin,” Nature Cell Biology, vol. 19, no. 7, pp. 856–863, 2017.

[93] V. Del Dotto, P. Mishra, S. Vidoni et al., “OPA1 Isoforms in the Hierarchical Organization of Mitochondrial Functions,” Cell Reports, vol. 19, no. 12, pp. 2557–2571, 2017.

[94] K. H. Flippo, Z. Lin, A. S. Dickey et al., “Deletion of a neuronal Drp1 activator protects against cerebral ischemia,” The Journal of Neuroscience, vol. 40, no. 15, pp. 3119–3129, 2020.

[95] X. Wu, W. Cui, W. Guo et al., “Acrolein aggravates secondary brain injury after intracerebral hemorrhage through Drp1-mediated mitochondrial oxidative damage in mice,” Neuroscience Bulletin, vol. 36, no. 10, pp. 1158–1170, 2020.

[96] D. Arnould, N. Rismanchi, A. Grodet et al., “Bak/Bak-Dependent Release of DDP/TIMM8a Promotes Drp1-Mediated Mitochondrial Fission and Mitophagy during Programmed Cell Death,” Current Biology, vol. 15, no. 23, pp. 2112–2118, 2005.

[97] S. Montessuit, S. P. Somasekharan, O. Terrones et al., “Membrane remodeling induced by the dynamin-related protein Drp1 stimulates Bax oligomerization,” Cell, vol. 142, no. 6, pp. 889–901, 2010.

[98] E. Filichia, B. Hoffer, X. Qi, and Y. Luo, “Inhibition of Drp1 mitochondrial translocation provides neural protection in dopaminergic system in a Parkinson’s disease model induced by MPTP,” Scientific Reports, vol. 6, no. 1, 2016.

[99] X.-m. Zhang, L. Zhang, G. Wang et al., “Suppression of mitochondrial fission in experimental cerebral ischemia: the potential neuroprotective target of p38 MAPK inhibition,” Neurochemistry International, vol. 90, pp. 1–8, 2015.

[100] M. He, Y. Ma, R. Wang, I. Zhang, L. Jing, and P. A. Li, “Deletion of mitochondrial uncoupling protein 2 exacerbates mitochondrial damage in mice subjected to cerebral reperfusion injury under both Normo- and hyperglycemic conditions,” International Journal of Biological Sciences, vol. 16, no. 15, pp. 2788–2802, 2020.

[101] L. F. Ferrari, A. Chum, O. Bogen, D. B. Reichling, and J. D. Levine, “Role of Drp1, a key mitochondrial fission protein, in neuropathic pain,” The Journal of Neuroscience, vol. 31, no. 31, pp. 11404–11410, 2011.

[102] G. de Arriba, M. Calvino, S. Benito, and T. Parra, “Cyclopamine A-induced apoptosis in renal tubular cells is related to oxidative damage and mitochondrial fission,” Toxicology Letters, vol. 218, no. 1, pp. 30–38, 2013.

[103] X. Zhang, H. Yan, Y. Yuan et al., “Cerebral ischemia-reperfusion-induced autophagy protects against neuronal...
Oxidative Medicine and Cellular Longevity

injury by mitochondrial clearance," *Autophagy*, vol. 9, no. 9, pp. 1321–1333, 2013.

[104] W. Zuo, S. Zhang, C.-Y. Xia, X.-F. Guo, W.-B. He, and N.-H. Chen, "Mitochondria autophagy is induced after hypoxic/ischemic stress in a Drp1 dependent manner: The role of inhibition of Drp1 in ischemic brain damage," *Neuropharmacology*, vol. 86, pp. 103–115, 2014.

[105] W. Zuo, Z. Liu, F. Yan, D. Mei, X. Hu, and B. Zhang, "Hyperglycemia abolished Drp1-mediated mitophagy at the early stage of cerebral ischemia," *European Journal of Pharmacology*, vol. 843, pp. 34–44, 2019.

[106] W.-J. Liu, H.-F. Jiang, F. U. L. Rehan et al., "Lycium barbarum polysaccharides decrease hyperglycemia-aggravated ischemic brain injury through maintaining mitochondrial fission and fusion balance," *International Journal of Biological Sciences*, vol. 13, no. 7, pp. 901–910, 2017.

[107] A. Santel and S. Frank, "Shaping mitochondria: The complex posttranslational regulation of the mitochondrial fission protein DRP1," *IUBMB Life*, vol. 60, no. 7, pp. 448–455, 2008.

[108] C. R. Chang and C. Blackstone, "Dynamic regulation of mitochondrial fission through modification of the dynamin-related protein Drp1," *Annals of the New York Academy of Sciences*, vol. 1201, pp. 34–39, 2010.

[109] X.-J. Han, Y.-F. Lu, S.-A. Li et al., "CaM kinase Iα-induced phosphorylation of Drp1 regulates mitochondrial morphology," *The Journal of Cell Biology*, vol. 182, no. 3, pp. 573–585, 2008.

[110] C.-H. Chou, C.-C. Lin, M.-C. Yang et al., "GSK3beta-mediated Drp1 phosphorylation induced elongated mitochondrial morphology against oxidative stress," *PLoS One*, vol. 7, no. 11, article e49112, 2012.

[111] I. Zaja, X. Bai, Y. Liu et al., "Cdk1, PKCδ and calcineurin-mediated Drp1 pathway contributes to mitochondrial fission-induced cardiomyocyte death," *Biochemical and Biophysical Research Communications*, vol. 453, no. 4, pp. 710–721, 2014.

[112] H. Otera, N. Ishihara, and K. Mihara, "New insights into the function and regulation of mitochondrial fission," *Biochimica et Biophysica Acta*, vol. 1833, no. 5, pp. 1256–1268, 2013.

[113] J. T. Cribbs and S. Strack, "Reversible phosphorylation of Drp1 by cyclic AMP-dependent protein kinase and calcineurin regulates mitochondrial fission and cell death," *EMBO Reports*, vol. 8, no. 10, pp. 939–944, 2007.

[114] N. Taguchi, N. Ishihara, A. Jofuku, T. Oka, and K. Mihara, "Mitotic phosphorylation of dynamin-related GTPase Drp1 participates in mitochondrial fission," *The Journal of Biological Chemistry*, vol. 282, no. 15, pp. 11521–11529, 2007.

[115] X. Qi, M.-H. Disatnik, N. Shen, R. A. Sobel, and D. Moehly-Rosen, "Aberant mitochondrial fission in neurons induced by protein kinase C(delta) under oxidative stress conditions in vivo," *Molecular Biology of the Cell*, vol. 22, no. 2, pp. 256–265, 2011.

[116] S. Strack, T. J. Wilson, and J. T. Cribbs, "Cyclin-dependent kinases regulate splice-specific targeting of dynamin-related protein 1 to microtubules," *The Journal of Cell Biology*, vol. 201, no. 7, pp. 1037–1051, 2013.

[117] J. A. Kashatus, A. Nascimento, L. J. Myers et al., "Erk2 phosphorylation of Drp1 promotes mitochondrial fission and MAPK-driven tumor growth," *Molecular Cell*, vol. 57, no. 3, pp. 537–551, 2015.

[118] A. Jahani-Asl, E. Huang, I. Irrcher et al., "CDK5 phosphorylates DRP1 and drives mitochondrial defects in NMDA-induced neuronal death," *Human Molecular Genetics*, vol. 24, no. 16, pp. 4573–4583, 2015.

[119] K. H. Flippo, A. Gnanasekaran, G. A. Perkins et al., "AKAP1 protects from cerebral ischemic stroke by inhibiting Drp1-dependent mitochondrial fission," *The Journal of Neuroscience*, vol. 38, no. 38, pp. 8233–8242, 2018.

[120] F. W. Herberg, A. Maleszka, T. Eide, L. Vossebein, and K. Tasken, "Analysis of A-kinase anchoring protein (AKAP) interaction with protein kinase A (PKA) regulatory subunits: PKA isoform specificity in AKAP binding," *Journal of Molecular Biology*, vol. 298, no. 2, pp. 329–339, 2000.

[121] C. R. Carlson, A. Ruppelt, and K. Tasken, "A Kinase anchoring protein (AKAP) interaction and dimerization of the Rla and Rlβ regulatory subunits of protein kinase A _in vivo_ by the yeast two hybrid system," *Journal of Molecular Biology*, vol. 327, no. 3, pp. 609–618, 2003.

[122] A. Carlucci, A. Adornetto, A. Scorziello et al., "Proteolysis of AKAP121 regulates mitochondrial activity during cellular hypoxia and brain ischaemia," *The EMBO Journal*, vol. 27, no. 7, pp. 1073–1084, 2008.

[123] H. Kim, M. C. Scimia, D. Wilkinson et al., "Fine-tuning of Drp1/Fis1 availability by AKAP121/Siah2 regulates mitochondrial adaptation to hypoxia," *Molecular Cell*, vol. 44, no. 4, pp. 532–544, 2011.

[124] G. G. Schiattarella, F. Cattaneo, G. Pironiti et al., "Akap1 deficiency promotes mitochondrial aberrations and exacerbates cardiac injury following permanent coronary ligation via enhanced mitophagy and apoptosis," *PLoS One*, vol. 11, no. 5, article e0154076, 2016.

[125] A. B. Knott, G. Perkins, R. Schwarzenbacher, and E. Bossy-Wetzel, "Mitochondrial fragmentation in neurodegeneration," *Nature Reviews. Neuroscience*, vol. 9, no. 7, pp. 505–518, 2008.

[126] H. Zhou, S. Wang, P. Zhu, S. Hu, Y. Chen, and J. Ren, "Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission," *Redox Biology*, vol. 15, pp. 335–346, 2018.

[127] X. Yang, H. Wang, H.-M. Ni et al., "Inhibition of Drp1 protects against seneceine-induced mitochondria-mediated apoptosis in primary hepatocytes and in mice," *Redox Biology*, vol. 12, pp. 264–273, 2017.

[128] L.-f. Fan, P.-y. He, Y.-c. Peng et al., "Mdivi-1 ameliorates early brain injury after subarachnoid hemorrhage via the suppression of inflammation-related blood-brain barrier disruption and endoplasmic reticulum stress-based apoptosis," *Free Radical Biology & Medicine*, vol. 112, pp. 336–349, 2017.

[129] X. Wang, W. Jiang, Y. Yan et al., "RNA viruses promote activation of the NLRP3 inflammasome through a RIP1-RIP3-DRP1 signaling pathway," *Nature Immunology*, vol. 15, no. 12, pp. 1126–1133, 2014.

[130] X. Wu, J. Luo, H. Liu et al., "Recombinant adipopectin peptide ameliorates brain injury following intracerebral hemorrhage by suppressing astrocyte-derived inflammation via the inhibition of Drp1-mediated mitochondrial fission," *Translational Stroke Research*, vol. 11, no. 5, pp. 924–939, 2020.

[131] L. Zhang, L. Wang, H. Xiao et al., "Tyrosine kinase Fyn promotes apoptosis after intracerebral hemorrhage in rats by activating Drp1 signaling," *Journal of Molecular Medicine (Berlin, Germany)*, vol. 99, no. 3, pp. 359–371, 2021.
[132] R. L. Jayaraj, S. Azimuth, R. Beirm, F. Y. Jalal, and G. A. Rosenberg, "Neuroinflammation: friend and foe for ischemic stroke," Journal of Neuroinflammation, vol. 16, no. 1, p. 142, 2019.

[133] Z. Liang, G. Wu, C. Fan et al., "The emerging role of signal transducer and activator of transcription 3 in cerebral ischemic and hemorrhagic stroke," Progress in Neurobiology, vol. 137, pp. 1–16, 2016.

[134] Q. Alhadidi and Z. A. Shah, "Cofilin mediates LPS-induced microglial cell activation and associated neurotoxicity through activation of NF-kB and JAK-STAT pathway," Molecular Neurobiology, vol. 55, no. 2, pp. 1676–1691, 2018.

[135] M. Guo, X. Wang, Y. Zhao et al., "Ketogenic diet improves brain ischemic tolerance and inhibits NLRP3 Inflammasome activation by preventing Drp1-mediated mitochondrial fission and endoplasmic reticulum stress," Frontiers in Molecular Neuroscience, vol. 11, p. 86, 2018.

[136] J. Estaquio and D. Arnould, "Inhibiting Drp1-mediated mitochondrial fission selectively prevents the release of cytochrome c during apoptosis," Cell Death and Differentiation, vol. 14, no. 6, pp. 1086–1094, 2007.

[137] S.-B. Ong, S. Subrayan, S. Y. Lim, S. M. Davidson, and D. J. Hausenloy, "Inhibiting mitochondrial fission protects the heart against ischemia/reperfusion injury," Circulation, vol. 121, no. 18, pp. 2012–2022, 2010.

[138] S. H. Graham and J. Chen, "Programmed cell death in cerebral ischemia," Journal of Cerebral Blood Flow and Metabolism, vol. 21, no. 2, pp. 99–109, 2001.

[139] R. Scherz-Shouval, E. Shvets, E. Fass, H. Shorer, L. Gil, and Z. Elazar, "Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4," The EMBO Journal, vol. 26, no. 7, pp. 1749–1760, 2007.

[140] J. Lee, S. Giordano, and J. Zhang, "Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling," The Biochemical Journal, vol. 441, no. 2, pp. 523–540, 2012.

[141] S. Mai, B. Muster, J. Berreiter-Hahn, and M. Jendrach, "Autophagy proteins LC3B, ATG5 and ATG12 participate in quality control after mitochondrial damage and influence lifespan," Autophagy, vol. 8, no. 1, pp. 47–62, 2012.

[142] M. Kundu and C. B. Thompson, "Autophagy: basic principles and relevance to disease," Annual Review of Pathology, vol. 3, no. 1, p. 427, 2008.

[143] N. Mizushima, B. Levine, A. M. Cuervo, and D. J. Klionsky, "Autophagy fights disease through cellular self-digestion," Nature, vol. 451, no. 7182, pp. 1069–1075, 2008.

[144] S. L. Yamashita and T. Kanri, "How autophagy eats large mitochondria: autophagosome formation coupled with mitochondrial fragmentation," Autophagy, vol. 13, no. 5, pp. 980–981, 2017.

[145] S. Song, J. Tan, Y. Miao, M. Li, and Q. Zhang, "Crosstalk of autophagy and apoptosis: involvement of the dual role of autophagy under ER stress," Journal of Cellular Physiology, vol. 232, no. 11, pp. 2977–2984, 2017.

[146] Z. Zhang, D. A. Sliter, C. K. E. Bleck, and S. Ding, "Fis1 deficiencies differentially affect mitochondrial quality in skeletal muscle," Mitochondrion, vol. 49, pp. 217–226, 2019.

[147] S. Kumari, L. Anderson, S. Farmer, S. L. Mehta, and P. A. Li, "Hyperglycemia alters mitochondrial fission and fusion proteins in mice subjected to cerebral ischemia and reperfusion," Translational Stroke Research, vol. 3, no. 2, pp. 296–304, 2012.

[148] E. A. Wappner, A. Institoris, S. Dutta, P. V. G. Katakam, and D. W. Busija, "Mitochondrial dynamics associated with oxygen-glucose deprivation in rat primary neuronal cultures," PLoS One, vol. 8, no. 5, article e63206, 2013.

[149] C. Peng, W. Rao, L. Zhang et al., "Mitofusin 2 ameliorates hypoxia-induced apoptosis via mitochondrial function and signaling pathways," The International Journal of Biochemistry & Cell Biology, vol. 69, pp. 29–40, 2015.

[150] U. Chimeh, M. A. Zimmerman, N. Gilyazova, and P. A. Li, "B355252, a novel small molecule, confers neuroprotection against cobalt chloride toxicity in mouse hippocampal cells through altering mitochondrial dynamics and limiting autophagy induction," International Journal of Medical Sciences, vol. 15, no. 12, pp. 1384–1396, 2018.

[151] X.-L. Chen, G.-P. Zhang, S.-L. Guo et al., "Mfn2-mediated preservation of mitochondrial function contributes to the protective effects of BHAPI in response to ischemia," Journal of Molecular Neuroscience, vol. 63, no. 3–4, pp. 267–274, 2017.

[152] X. Wu, J. Luo, H. Liu, W. Cui, D. Feng, and Y. Qu, "SIRT3 protects against early brain injury following subarachnoid hemorrhage via promoting mitochondrial fusion in an AMPK dependent manner," Chinese Neurosurgical Journal, vol. 6, no. 1, 2020.

[153] W.-J. Duan, Y.-F. Li, F.-L. Liu et al., "A SIRT3/AMPK/autophagy network orchestrates the protective effects of trans-resveratrol in stressed peritoneal macrophages and RAW 264.7 macrophages," Free Radical Biology & Medicine, vol. 95, pp. 230–242, 2016.

[154] D. Carling, "AMPK signalling in health and disease," Current Opinion in Cell Biology, vol. 45, pp. 31–37, 2017.

[155] H. Dong, W. Zhou, J. Xin et al., "Salvinorin A moderates postischemic brain injury by preserving endothelial mitochondrial function via AMPK/Mfn2 activation," Experimental Neurology, vol. 322, p. 113045, 2019.

[156] T. Shen, M. Zheng, C. Cao et al., "Mitofusin-2 is a major determinant of oxidative stress-mediated heart muscle cell apoptosis," The Journal of Biological Chemistry, vol. 282, no. 32, pp. 23354–23361, 2007.

[157] K. Singaravelu, C. Nelson, D. Bakowski et al., "Mitofusin 2 regulates STIM1 migration from the Ca²⁺ store to the plasma membrane in cells with depolarized mitochondria," The Journal of Biological Chemistry, vol. 286, no. 14, pp. 12189–12201, 2011.

[158] G. A. Ngoh, K. N. Papanicolaou, and K. Walsh, "Loss of mitofusin 2 promotes endoplasmic reticulum stress," The Journal of Biological Chemistry, vol. 287, no. 24, pp. 20321–20332, 2012.

[159] A. Martorell-Riera, M. Segarra-Mondejar, J. P. Muñoz et al., "Mfn2 downregulation in excitotoxicity causes mitochondrial dysfunction and delayed neuronal death," The EMBO Journal, vol. 33, no. 20, pp. 2388–2407, 2014.

[160] D. F. Suen, K. L. Norris, and R. J. Youle, "Mitochondrial dynamics and apoptosis," Genes & Development, vol. 22, no. 12, pp. 1577–1590, 2008.

[161] T. Ichinohe, T. Yamazaki, T. Koshiba, and Y. Yanagi, "Mitochondrial protein mitofusin 2 is required for NLRP3 inflammasome activation after RNA virus infection," Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 44, pp. 17963–17968, 2013.

[162] S. Li, X. Sun, L. Xu et al., "Baicalin attenuates in vivo and in vitro hyperglycemia-exacerbated ischemia/reperfusion..."
injury by regulating mitochondrial function in a manner dependent on AMPK,” *European Journal of Pharmacology*, vol. 815, p. 118, 2017.

[163] M. Karbowski, K. L. Norris, M. M. Cleland, S.-Y. Jeong, and R. J. Youle, “Role of Bax and Bak in mitochondrial morphogenesis,” *Nature*, vol. 443, no. 7112, pp. 658–662, 2006.

[164] C. Brooks, Q. Wei, L. Feng et al., “Bak regulates mitochondrial morphology and pathology during apoptosis by interacting with mitofusins,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 104, no. 28, pp. 11649–11654, 2007.

[165] M. M. Cleland, K. L. Norris, M. Karbowski et al., “Bcl-2 family interaction with the mitochondrial morphogenesis machinery,” *Cell Death and Differentiation*, vol. 18, no. 2, pp. 235–247, 2011.

[166] S. Hoppins, F. Edlich, M. M. Cleland et al., “The soluble form of Bax regulates mitochondrial fusion via MFN2 homotypic complexes,” *Molecular Cell*, vol. 41, no. 2, pp. 150–160, 2011.

[167] W. Liu, F. Tian, T. Kurata, N. Morimoto, and K. Abe, “Dynamic changes of mitochondrial fusion and fission proteins after transient cerebral ischemia in mice,” *Journal of Neuroscience Research*, vol. 90, no. 6, pp. 1183–1189, 2012.

[168] Y. Chen and G. W. Dorn, “2ND. PINK1-phosphorylated mitofusin 2 is a Parkin receptor for culling damaged mitochondria,” *Science*, vol. 340, no. 6131, pp. 471–475, 2013.

[169] W.-K. Ju, M. S. Shim, K.-Y. Kim et al., “Inhibition of cAMP/PKA pathway protects optic nerve head astrocytes against oxidative stress by Akt/Bax phosphorylation-mediated Mfn1/2 oligomerization,” *Oxidative Medicine and Cellular Longevity*, vol. 2019, 16 pages, 2019.

[170] M. Neuspiel, R. Zunino, S. Gangaraju, P. Rippstein, and H. McBride, “Activated mitofusin 2 signals mitochondrial fusion, interferes with Bax activation, and reduces susceptibility to radical induced depolarization,” *The Journal of Biological Chemistry*, vol. 280, no. 26, pp. 25060–25070, 2005.

[171] I. Rutkai, I. Merdzo, S. V. Wunnava, G. T. Curtin, P. G. Katakam, and D. W. Busija, “Cerebrovascular function and mitochondrial bioenergetics after ischemia-reperfusion in male rats,” *Journal of Cerebral Blood Flow and Metabolism*, vol. 39, no. 6, pp. 1056–1068, 2019.

[172] P. Yu-Wai-Man, M. I. Trerell, K. G. Hollingsworth, P. G. Griffiths, and P. F. Chinney, “OPA1 mutations impair mitochondrial function in both pure and complicated dominant optic atrophy,” *Brain*, vol. 134, Part 4, 2011.

[173] E. D. dong, J. A. Wagner, S. W. Gorsich, J. M. McCaffery, J. M. Shaw, and J. Nunnari, “The dynamin-related GTPase, Mgm 1p, is an intermembrane space protein required for maintenance of fusion competent mitochondrial membranes and ER stress,” *Molecular and Cellular Proteomics*, vol. 8, no. 12, pp. 343–352, 2009.

[174] A. Olicon, L. Baricault, N. Gas et al., “Loss of OPA1 perturbs the mitochondrial inner membrane structure and integrity, leading to cytochrome c release and apoptosis,” *The Journal of Biological Chemistry*, vol. 278, no. 10, pp. 7743–7746, 2003.

[175] D. Arnolft, A. Grodet, Y.-J. Lee, J. Estaquier, and C. Blackstone, “Release of OPA1 during apoptosis participates in the rapid and complete release of cytochrome c and subsequent mitochondrial fragmentation,” *The Journal of Biological Chemistry*, vol. 280, no. 42, pp. 35742–35750, 2005.

[176] R. Kumar, M. J. Bukowski, J. M. Wider et al., “Mitochondrial dynamics following global cerebral ischemia,” *Molecular and Cellular Neurosciences*, vol. 76, pp. 68–75, 2016.

[177] T. Varanita, M. E. Soriano, V. Romanello et al., “The Opa1-dependent mitochondrial cristae remodeling pathway controls atrophic, apoptotic, and ischemic tissue damage,” *Cell Metabolism*, vol. 21, no. 6, pp. 834–844, 2015.

[178] T. Zhang, S. Xu, P. Wu et al., “Mitoquinone attenuates blood-brain barrier disruption through Nrf2/PHB2/OPA1 pathway after subarachnoid hemorrhage in rats,” *Experimental Neurology*, vol. 317, p. 1, 2019.

[179] Y. Chen, J. Chen, X. Sun et al., “Evaluation of the neuroprotective effect of EGCG: a potential mechanism of mitochondrial dysfunction and mitochondrial dynamics after subarachnoid hemorrhage,” *Food & Function*, vol. 9, no. 12, pp. 6349–6359, 2018.

[180] L. Zhang, Z. He, Q. Zhang et al., “Exercise pretreatment promotes mitochondrial dynamic protein OPA1 expression after cerebral ischemia in rats,” *International Journal of Molecular Sciences*, vol. 15, no. 3, pp. 4453–4463, 2014.

[181] T. H. Sanderson, S. Raghunayakula, and R. Kumar, “Neuronal hypoxia disrupts mitochondrial fusion,” *Neuroscience*, vol. 301, p. 71, 2015.

[182] S. Chalmers and D. G. Nicholls, “The Relationship between Free and Total Calcium Concentrations in the Matrix of Liver and Brain Mitochondria,” *The Journal of Biological Chemistry*, vol. 278, no. 21, pp. 19062–19070, 2003.

[183] L. X. Zhang, M. Raghavan, and L. S. Satin, “The Endoplasmic Reticulum and Calcium Homeostasis in Pancreatic Beta Cells,” *Endocrinology*, vol. 161, no. 2, 2020.

[184] T. Kalogeris, C. P. Baines, M. Krenz, and R. J. Korthuis, “Cell biology of ischemia/reperfusion injury,” *International Review of Cell and Molecular Biology*, vol. 298, pp. 229–317, 2012.

[185] R. Brouns and P. P. De Deyn, “The complexity of neurobiological processes in acute ischemic stroke,” *Clinical Neurology and Neurosurgery*, vol. 111, no. 6, pp. 483–495, 2009.

[186] K. Szydłowska and M. Tymianski, “Calcium, ischemia and excitotoxicity,” *Cell Calcium*, vol. 47, no. 2, pp. 122–129, 2010.

[187] A. R. Van Vliet and P. Agostinis, “Mitochondria-associated membranes and ER stress,” *Current Topics in Microbiology and Immunology*, vol. 414, pp. 73–102, 2017.

[188] G. Morris, B. K. Puri, K. Walder et al., “The endoplasmic reticulum stress response in neuroprogressive diseases: emerging pathophysiological role and translational implications,” *Molecular Neurobiology*, vol. 55, no. 12, pp. 8765–8787, 2018.

[189] R. D. Readnower, J. D. Pandya, M. L. McEwen, J. R. Pauly, J. E. Springer, and P. G. Sullivan, “Post-injury administration of the mitochondrial permeability transition pore inhibitor, NIM811, is neuroprotective and improves cognition after traumatic brain injury in rats,” *Journal of Neurotrauma*, vol. 28, no. 9, pp. 1845–1853, 2011.

[190] W. Paschen and T. Mengesdorf, “Endoplasmic reticulum stress response and neurodegeneration,” *Cell Calcium*, vol. 38, no. 3-4, pp. 409–415, 2005.

[191] K. Nagamine, J. Kodoh, S. Minoshima et al., “Molecular cloning of a novel putative Ca2+ channel protein (TRPC7) highly expressed in brain,” *Genomics*, vol. 54, no. 1, pp. 124–131, 1998.
[192] D. E. Clapham, L. W. Runnels, and C. Strübing, “The trp ion channel family,” *Nature Reviews. Neuroscience*, vol. 2, no. 6, pp. 387–396, 2001.

[193] E. Wehage, J. Eisfeld, I. Heiner, E. Jüngling, C. Zitt, and A. Lückhoff, “Activation of the cation channel long transient receptor potential channel 2 (LTRPC2) by hydrogen peroxide,” *The Journal of Biological Chemistry*, vol. 277, no. 26, pp. 23150–23156, 2002.

[194] Y. Hara, M. Wakamori, M. Ishii et al., “LTRPC2 Ca\(^{2+}\)-permeable channel activated by changes in redox status confers susceptibility to cell death,” *Molecular Cell*, vol. 9, no. 1, pp. 163–173, 2002.

[195] J. Jia, S. Verma, S. Nakayama et al., “Sex differences in neuroprotection provided by inhibition of TRPM2 channels following experimental stroke,” *Journal of Cerebral Blood Flow and Metabolism*, vol. 31, no. 11, pp. 2160–2168, 2011.

[196] T. Shimizu, T. A. Macey, N. Quillinan et al., “Androgen and PARP-1 regulation of TRPM2 channels after ischemic injury,” *Journal of Cerebral Blood Flow and Metabolism*, vol. 33, no. 10, pp. 1549–1555, 2013.

[197] M. Ye, W. Yang, J. F. Ainscough et al., “TRPM2 channel deficiency prevents delayed cytosolic Zn\(^{2+}\) accumulation and CA1 pyramidal neuronal death after transient global ischemia,” *Cell Death & Disease*, vol. 5, no. 11, article e1541, 2014.

[198] Q. Wang, N. Liu, Y.-S. Ni et al., “TRPM2 in ischemic stroke: structure, molecular mechanisms, and drug intervention,” *Channels*, vol. 15, no. 1, pp. 136–154, 2021.

[199] A. Secondo, T. Petrozziello, V. Tedeschi et al., “ORAI1/STIM1 interaction intervenes in stroke and in neuroprotection induced by ischemic preconditioning through store-operated calcium entry,” *Stroke*, vol. 50, no. 5, pp. 1240–1249, 2019.

[200] M. Lebiedzinska, G. Szabadkai, A. W. E. Jones, J. Duszynski, and M. R. Wieckowski, “Interactions between the endoplasmic reticulum, mitochondria, plasma membrane and other subcellular organelles,” *The International Journal of Biochemistry & Cell Biology*, vol. 41, no. 10, pp. 1805–1816, 2009.

[201] G. Szabadkai and M. R. Duchen, “Mitochondria: the hub of cellular Ca\(^{2+}\) signaling,” *Physiology (Bethesda)*, vol. 23, pp. 84–94, 2008.

[202] R. Bravo-Sagua, V. Parra, C. López-Crisosto, P. Diaz, A. F. G. Quest, and S. Lavandero, “Calcium transport and signaling in mitochondria,” *Comprehensive Physiology*, vol. 7, no. 2, pp. 623–634, 2017.